Sickle cell disease is a blood condition seen most commonly in people of African ancestry. Clinically significant sickle cell syndromes also occur in people of Mediterranean, Middle Eastern or (east) Indian background. Here, the most common problem is a combination sickle cell and beta thalassemia genes. The sickle cell mutation reflects a single change in the amino acid building blocks of the oxygen-transport protein, hemoglobin. This protein, which is the component that gives red cells their color, has two subunits. The alpha subunit is normal in people with sickle cell disease. The ß-subunit has the amino acid valine at position 6 instead of the glutamic acid that is normally present. The alteration is the basis of all the problems that occur in people with sickle cell disease. The schematic diagram shows the first eight of the 146 amino acids in the ß-globin subunit of the hemoglobin molecule. The amino acids of the hemoglobin protein are represented as a series of linked, colored boxes. The lavender box represents the normal glutamic acid at position 6. The dark green box represents the valine in sickle cell hemoglobin. The other amino acids in sickle and normal hemoglobin are identical.
The molecule, DNA (deoxyribonucleic acid), is the fundamental genetic material that determines the arrangement of the amino acid building blocks in all proteins. Segments of DNA that code for particular proteins are called genes. The gene that controls the production of the ß-globin subunit of hemoglobin is located on one of the 46 human chromosomes (chromosome #11). People have twenty-two identical chromosome pairs (the twenty-third pair is the unlike X and Y chromosomes that determine a person's sex). One of each pair is inherited from the father, and one from the mother. Occasionally, a gene is altered in the exchange between parent and offspring. This event, called mutation, occurs extremely rarely. Therefore, the inheritance of sickle cell disease depends totally on the genes of the parents.
If only one of the ß-globin genes is the "sickle" gene and the other is normal, the person is a carrier for sickle cell disease. The condition is called sickle cell trait. With a few rare exceptions, people with sickle cell trait are completely normal. If both ß-globin genes code for the sickle protein, the person has sickle cell disease. Sickle cell disease is determined at conception, when a person acquires his/her genes from the parents. Sickle cell disease cannot be caught, acquired, or otherwise transmitted. Further, sickle cell trait does not develop into sickle cell disease.
The hemoglobin molecule (made of alpha and ß-globin subunits) picks up oxygen in the lungs and releases it when the red cells reach peripheral tissues, such as the muscles. Ordinarily, the hemoglobin molecules exist as single, isolated units in the red cell, whether they have oxygen bound or not. Normal red cells maintain a basic disc shape, whether they are transporting oxygen or not.
The picture is different with sickle hemoglobin. Sickle hemoglobin exists as isolated units in the red cells when they have oxygen bound. When sickle hemoglobin releases oxygen in the peripheral tissues, however, the molecules tend to stick together and form long chains or polymers. These polymers distort the cell and cause it to bend out of shape. When the red cells return to the lungs and pick up oxygen again, the hemoglobin molecules resume their solitary existence (the left of the diagram).
A single red cell may traverse the circulation four times in one minute. Sickle hemoglobin undergoes repeated episodes of polymerization and depolymerization. This cyclic alteration in the state of the molecules damages the hemoglobin and ultimately the red cell itself.
Polymerized sickle hemoglobin does not form single strands. Instead, the molecules group in long bundles of 14 strands each that twist in a regular fashion, much like a braid. 
These bundles self-associate into even larger structures that stretch and distort the cell. An analogy would be a water balloon which was stretched and deformed by ice sickles. The stretching of the balloon's rubber is similar to what happens to the membrane of the red cell.
Despite their imposing appearance, the forces that hold these sickle hemoglobin polymers together are very weak. The abnormal valine amino acid at position 6 in the ß-globin chain interacts weakly with the ß-globin chain in an adjacent sickle hemoglobin molecule. The complex twisting, 14-strand structure of the bundles produces multiple interactions and cross-interactions between molecules. On the other hand, the weak nature of the interaction opens one strategy to treat sickle cell disease.
Some types of hemoglobin molecules, such as that found before birth (fetal hemoglobin), block the interactions between the deoxygenated hemoglobin S molecules. All people have fetal hemoglobin in their circulation before birth. Fetal hemoglobin protects the unborn child and newborns from the effects of sickle cell hemoglobin. Unfortunately, this hemoglobin disappears within the first year after birth. One approach to treating sickle cell disease is to rekindle production of fetal hemoglobin. The drug, hydroxyurea induces fetal hemoglobin production in some patients with sickle cell disease and improves the clinical condition of some patients.
The schematic diagram shows the changes that occur as sickle or normal red cells release oxygen in the microcirculation. The upper panel shows that normal red cells retain their biconcave shape and move through the microcirculation (capillaries) without problem. In contrast, the hemoglobin polymerizes in sickle red cells when they release oxygen, as shown in the lower panel. The polymerization of hemoglobin deforms the red cells. The problem, however, is not simply one of abnormal shape. The membranes of the cells are rigid due in part to repeated episodes of hemoglobin polymerization/depolymerization as the cells pick up and release oxygen in the circulation. These rigid cells fail to move through the microcirculation, blocking local blood flow to a microscopic region of tissue. Amplified many times, these episodes produce tissue hypoxia (low oxygen supply). The result is pain, and often damage to organs. The damage to red cell membranes plays an important role in the development of complications in sickle cell disease. Robert Hebbel at the University of Minnesota and colleagues were among the first workers to show that the heme component of hemoglobin tends to be released from the protein with repeated episodes of sickle hemoglobin polymerization. Some of this free heme lodges in the red cell membrane. The iron in the center of the heme molecule promotes formation of very dangerous compounds, called oxygen radicals. These molecules damage both the lipid and protein components of the red cell membrane. As a consequence, the membranes become stiff. Also, the damaged proteins tend to clump together to form abnormal clusters in the red cell membrane. Antibodies develop to these protein clusters, leading to even more red cell destruction (hemolysis).
The anemia in sickle cell disease is caused by red cell destruction, or hemolysis. The production of red cells by the bone marrow increases dramatically, but is unable to keep pace with the destruction. Red cell production increases by five to ten-fold in most patients with sickle cell disease. The average half-life of normal red cells is about 40 days. In patients with sickle cell disease, this value can fall to as low as four days. The volume of "active" bone marrow is much greater in patients with sickle cell disease relative to normal due to the demand for greater red cell production.
The degree of anemia varies widely between patients. In general, patients with sickle cell disease have hematocrits that are roughly half the normal value (e.g., about 25% compared to about 40-45% normally). Patients with hemoglobin SC disease (where one of the ß-globin genes codes for hemoglobin S and the other for the variant, hemoglobin C) have higher hematocrits than do those with homozygous Hb SS disease. The hematocrits of patients with Hb SC disease run in low- to mid-thirties. The hematocrit is normal for people with sickle cell trait.
